Identification of Novel Agents to Treat PTSD using Clinical Data

利用临床数据鉴定治疗 PTSD 的新药

• 批准号: 10579848
• 负责人: Jaimie L. Gradus
• 金额: $ 53.98万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-01 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10579848
• 关键词: Address; Adverse event; Antidepressive Agents; Biological Psychiatry; Clinical Data; Clinical effectiveness; Complex; Data; Data Set; Data Sources; Development; Diagnosis; Disease remission; Drug Prescriptions; Effectiveness; Evaluation; Fluoxetine; Future; Healthcare Systems; Institution; Label; Leadership; Medical; Medical Records; Methods; National Institute of Mental Health; Outcome; Paroxetine; Patients; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacological Treatment; Pharmacotherapy; Population; Post-Traumatic Stress Disorders; Probability; Process; Psychopharmacology; Psychotherapy; Psychotropic Drugs; Publishing; Recommendation; Registries; Reporting; Research; Resources; Retrospective cohort; Scanning; Sertraline; Severities; Symptoms; Therapeutic Agents; Time; Trees; United States Department of Veterans Affairs; United States Food and Drug Administration; Veterans; Veterans Health Administration; Work; comorbidity; data mining; data resource; design; effective therapy; evidence base; evidence based guidelines; improved; machine learning method; military veteran; new therapeutic target; novel; novel therapeutics; off-label drug; pharmacologic; prospective; psychopharmacologic; research clinical testing; response; statistics; symptomatic improvement; therapy development; treatment guidelines; venlafaxine; working group

PROJECT SUMMARY This study will leverage large-scale clinical data from the Department of Veterans Affairs (VA) to identify existing pharmaceutical agents commonly prescribed for a multitude of indications that are incidentally associated with improvements in post-traumatic stress disorder (PTSD) symptoms. Through prior efforts, a data source containing almost 20 years of treatment data on all (over one million) VA users diagnosed with PTSD between October 1999 and February 2018 has been constructed, including a complete historical record of their evidence-based medication and psychotherapy receipt within the VA healthcare system. Importantly, the team has also amassed symptom-level patient-reported PTSD outcome data for hundreds of thousands of these patients. The existing data is a powerful resource with which the research team proposes to explore the following specific aims: (1) identify off-label pharmaceutical agents associated with improvements in PTSD symptoms over time; (2) further evaluate the clinical effectiveness of newly-identified off-label pharmaceutical agents for improvement in PTSD symptoms using rigorous causal methods; and (3) identify common adverse events related to off-label pharmaceutical agents associated with improvements in PTSD symptoms in this complex, psychiatrically and medically ill population The proposed project will identify agents that may merit further rigorous clinical evaluation for psychiatric benefit. New therapeutic targets may be identified that will lead to greater treatment options or specific treatments. Further, identification of off-label medications that improve or have contraindicated effects for psychiatric populations will provide critical guidance to practicing clinicians.

项目总结

项目成果

Comparative Effectiveness of Direct-Acting Antivirals for Posttraumatic Stress Disorder in Veterans Affairs Patients With Hepatitis C Virus Infection.

直接作用抗病毒药物治疗丙型肝炎病毒感染退伍军人事务部患者创伤后应激障碍的比较疗效。

• DOI: 10.1093/aje/kwac104
• 发表时间: 2022
• 期刊: American journal of epidemiology
• 影响因子: 5
• 作者: Shiner,Brian;Huybrechts,Krista;Gui,Jiang;Rozema,Luke;Forehand,Jenna;Watts,BradleyV;Jiang,Tammy;Hoyt,JessicaE;Esteves,Jack;Schnurr,PaulaP;Ray,Kristen;Gradus,JaimieL
• 通讯作者: Gradus,JaimieL

Mining Clinical Data for Novel Posttraumatic Stress Disorder Medications.

• DOI: 10.1016/j.biopsych.2021.10.008
• 发表时间: 2022-04-01
• 期刊: Biological psychiatry
• 影响因子: 10.6
• 作者: Shiner B;Forehand JA;Rozema L;Kulldorff M;Watts BV;Trefethen M;Jiang T;Huybrechts KF;Schnurr PP;Vincenti M;Gui J;Gradus JL
• 通讯作者: Gradus JL

Safety of Glecaprevir/Pibrentasvir for hepatitis C in patients with posttraumatic stress disorder: A post-marketing surveillance study.

Glecaprevir/Pibrentasvir 对于创伤后应激障碍患者治疗丙型肝炎的安全性：一项上市后监测研究。

• DOI: 10.1016/j.genhosppsych.2023.06.012
• 发表时间: 2023
• 期刊: General hospital psychiatry
• 影响因子: 7
• 作者: Shiner,Brian;Park,JennaA;Rozema,Luke;Hoyt,JessicaE;Watts,BradleyV;Gradus,JaimieL
• 通讯作者: Gradus,JaimieL